Health Trials

KRAS G12C Mutation Advanced Solid Tumor

1

Review clinical trials related to KRAS G12C Mutation Advanced Solid Tumor. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.

This is a multicenter, open-label phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HS-10541 as monotherapy or in combination with other anti-cancer therapies in participants with KRAS G12C mutation advanced solid tumors.

Participants needed: 636
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.Updated: May 29, 2026
Eligibility criteria

Voluntary participation and written informed consent.. [+8]

Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion requi... [+11]

Read more